Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : TM Bioscience Corp. tmc.v -- Ignore unavailable to you. Want to Upgrade?

To: Rhys Roberts who wrote (109)	5/20/1999 2:10:00 PM
From: Rhys Roberts	Read Replies (1) \| Respond to of 137

Tm Bioscience granted U.S. patent - 3rd Patent extends Tm's position in DNA diagnostic and biochip technologies - TORONTO, May 20 /CNW/ - VSE - TMC Tm Bioscience, a leader in the development of DNA (nucleic acids) technologies, is pleased to announce that U.S. Patent No. 5902724 has been granted for Tm's signal amplification system. The patent covers the Company's universal signal amplification system which improves the detection sensitivity of DNA-based and other medical diagnostic tests. Current DNA tests often lack sufficient sensitivity or require complex and expensive methodology to detect mutations or pathogens like the AIDS virus. Tm's signal-amplifier provides a simple and cost-effective solution to this problem. Using this system the Company has demonstrated up to a 100,000-fold improvement in the sensitivity of specific tests and believes that this can be extended even further. ''This is a very valuable and timely event as we continue to commercialize our technologies,'' said Dr. Richard Janeczko, V.P. Business Development. ''Our signal amplification system has broad-based applications and directly addresses key issues of cost, complexity and sensitivity in many DNA tests. It is the third patent issued to us recently and significantly strengthens our position in the DNA diagnostic and biochip markets. It will be pivotal in advancing our commercialization strategy of licensing our technologies to the major manufacturers of these types of tests.'' The Company's Annual General Meeting will be held in Toronto, Ontario on Tuesday June 1, 1999 at 4:00pm at the Toronto Board of Trade. Tm Bioscience is an emerging Canadian biotechnology company developing and commercializing proprietary DNA based technologies for application in biochips, diagnostics and genomic analysis. The Company offers pharmaceutical and biotechnology companies the ability to develop novel nucleic acid-based products for medical and research applications. Additional information about Tm Bioscience can be found at www.tmbioscience.com. Tm Bioscience trades on the Vancouver Stock Exchange under the symbol TMC and has approximately 69 million shares outstanding. THE VANCOUVER STOCK EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY AND ACCURACY OF THIS NEWS RELEASE. -0- 05/20/1999 For further information: Don MacAdam, President & CEO, (416) 593-4323, (416) 593-1066 fax, dmacadam@tmbioscience.com; Jay Hussey, Investor and Media Inquiries, (416) 815-0700, ext. 225, (416) 815-0080 fax; jhussey@equicomgroup.com